MAPT and Alzheimer disease: For this analysis, we first focused on the hippocampus and TCx of non-demented CTRL donors with no pathology (n = 8) and donors with AD neuropathologic change defined as tau neurofibrillary degeneration and neuritic plaque density (n = 12; Supplementary dataset 3, online resource), which are well-defined opposite extremes of AD pathology.